Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Lisdexamfetamine Safe and Effective Therapy for Adult Attention-Deficit Hyperactivity Disorder: Presented at CINP By Bryan DeBusk, PhD MUNICH, Germany -- July 18, 2008 -- The prodrug stimulant lisdexamfetamine (LDX) safely and effectively improves measures of attention-deficit hyperactivity disorder (ADHD) in adults, according to research presented here at the 26th Collegium Internationale Neuro-Psychopharmacologicum (CINP) Congress. The results were presented in a poster session on July 16 by David Goodman, MD, Johns Hopkins University School of Medicine, Baltimore, Maryland, and Adult Attention Deficit Disorder Centre of Maryland, Lutherville, Maryland. After a 7- to 28-day washout period, 481 patients (aged 18 to 55 years) with moderate to severe ADHD were randomised to 4 weeks of treatment with LDX at a daily dose of 30 mg (n = 115), 50 mg (n = 117), or 70 mg (n = 120) or to placebo. ADHD Rating Scale (ADHD-RS) scores were well-matched across groups at baseline. Patients in the LDX groups achieved better scores on the ADHD-RS compared with placebo (30 mg, -16.2; 50 mg, -17.4; 70 mg, -18.6; placebo, -8.2; all P < .0001). No differences were noted among the different dosages of LDX. Improvements were noted as early as 1 week after the start of treatment (30 mg, -12.2; 50 mg, -11.5; 70 mg, -13.4; placebo, -5.7; all P < .0001). Patients in the LDX group reported decreased appetite (27%), dry mouth (26%), and insomnia (19%). No differences were seen in overall sleep quality between LDX-treated groups and placebo as subjectively measured by the Pittsburgh Sleep Questionnaire at baseline and follow-up. Most patients reported a lessening of adverse effects over the course of the study. Dr. Goodman expects the results will encourage physicians to consider LDX for adult patients with ADHD. "Hopefully, physicians will acknowledge the validity of adult ADHD and prescribe long-acting, once-daily, low-abuse-potential medications for these patients," he concluded. Funding for this study was provided by Shire Pharmaceuticals. [Presentation title: Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder. Abstract P10-15] E-mail this page to a friend or colleague! To print, use this version